Patents by Inventor James D. Banting
James D. Banting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7393825Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to 1/20) of those known to induce vasodilation in “normal” circulations.Type: GrantFiled: June 11, 2003Date of Patent: July 1, 2008Assignee: Strakan International LimitedInventors: Jeremy P. W. Heaton, Michael A. Adams, James D. Banting
-
Patent number: 6610652Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations.Type: GrantFiled: March 8, 2002Date of Patent: August 26, 2003Assignee: Queen's University at KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton, James D. Banting
-
Patent number: 6586391Abstract: The mechanism of hypertension following acute NO synthase blockage is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a ‘normal’ physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.Type: GrantFiled: July 18, 2000Date of Patent: July 1, 2003Assignee: Queen's University at KingstonInventors: James D. Banting, Jeremy P. W. Heaton, Michael A. Adams
-
Publication number: 20020193307Abstract: The mechanism of hypertension following acute NO synthase blockade is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a ‘normal’ physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.Type: ApplicationFiled: March 11, 2002Publication date: December 19, 2002Applicant: Queen's University at KingstonInventors: James D. Banting, Jeremy P.W. Heaton, Michael A. Adams
-
Patent number: 6423683Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations.Type: GrantFiled: July 11, 2000Date of Patent: July 23, 2002Assignee: Queens University at KingstonInventors: Jeremy P. W. Heaton, Michael A. Adams, James D. Banting
-
Publication number: 20020091088Abstract: Methods for treating vascular conditions associated with localized imbalance in vascular tone, which are hypothesized to be largely due to elevated endothelin (ET) are provided. The methods involve administration of nitric oxide (NO), agents which are able to provide NO, such as NO donors, agents which activate guanyl cyclase, such as YC-1, or agents which prolong the actions of endogenous NO or cyclic guanosine monophosphate (cGMP; a 2nd messenger molecule), such as phosphodiesterase (PDE) inhibitors. According to the invention, such agents are administered in minimal doses or microdoses by any route known in the art, so as to provide dosages which are about one half to about one twentieth (½ to {fraction (1/20)}) of those known to induce vasodilation in “normal” circulations.Type: ApplicationFiled: March 8, 2002Publication date: July 11, 2002Applicant: Queen's University at KingstonInventors: Jeremy P.W. Heaton, Michael A. Adams, James D. Banting
-
Patent number: 6410007Abstract: The mechanism of hypertension following acute NO synthase blockage is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a ‘normal’ physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.Type: GrantFiled: September 14, 1998Date of Patent: June 25, 2002Assignee: Queen's University at KingstonInventors: James D. Banting, Jeremy P. W. Heaton, Michael A. Adams
-
Patent number: 6200288Abstract: An everting toroid for use in delivering a powdered, fluid, or aerosolized pharmaceutical composition, or other composition, to an internal body cavity, such as the urethra, or other cavity, is contained within a tubular housing and may be extended therefrom and retracted back into the tubular housing. The composition may be distributed on the surface of the everting toroid when made from an impermeable membrane, contained within the toroid when made from a permeable membrane, or may be injected through the lumen thereof via an aerosol wand which releases the composition as the toroid and/or wand are withdrawn from the cavity.Type: GrantFiled: January 29, 1999Date of Patent: March 13, 2001Assignee: Queen's University at KingstonInventors: Jeremy P. W. Heaton, Michael A. Adams, James D. Banting
-
Patent number: 6165975Abstract: A method of treatment, in an organism, of a vascular condition, comprising administration of at least one agent at a level which enhances NO and which does not appreciably alter normal systemic vascular tone in said organism. At least one agent is an NO donor selected from the group consisting of glyceryl trinitrate, isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside, 3-morpholinosydnonimine molsidomine, S-nitroso-N-acetylpenicillamine, S-nitrosoglutathione, and N-hydroxy-L-arginine.Type: GrantFiled: December 22, 1999Date of Patent: December 26, 2000Assignee: Queen's University at KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton, James D. Banting
-
Patent number: 5954688Abstract: An everting toroid for use in delivering a powdered or liquid or aerosolized drug to an internal body cavity, such as the urethra, is described. The drug may be distributed on the surface of the everting toroid or may be injected through the lumen thereof via an aerosol wand which is designed to release the drug as the toroid and/or wand are withdrawn from the body cavity.Type: GrantFiled: August 26, 1997Date of Patent: September 21, 1999Assignee: Queen's University at KingstonInventors: Michael A. Adams, Jeremy P. W. Heaton, James D. Banting
-
Patent number: 5688499Abstract: The mechanism of hypertension following acute NO synthase blockade is via endothelin mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a `normal` physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction.Type: GrantFiled: March 13, 1996Date of Patent: November 18, 1997Assignee: Queen's University at KingstonInventors: James D. Banting, Jeremy P.W. Heaton, Michael A. Adams